The significant improvement in the lipid profile (LDL-C, non-HDL-C, ApoB, VLDL-C, remnant cholesterol, and TGs) of individuals with T2DM with or without AD treated with evolocumab could be explained by the increase in the LDL receptor (LDLR) expression in the liver, which recognizes both ApoB100 on LDL and ApoE on VLDL and IDL. Here, LDLR is linked to type 2 diabetes mellitus.